EyePoint Pharmaceuticals Trial Misses Primary Goal for Duravyu

By Adam Feuerstein · STAT News · 2026-08-17

According to STAT News, EyePoint Pharmaceuticals recently announced that its experimental wet AMD treatment, Duravyu, failed to meet the main target in a Phase 3 clinical study. The drug was unable to show it could preserve vision with fewer injections when compared to the curren

According to STAT News, EyePoint Pharmaceuticals recently announced that its experimental wet AMD treatment, Duravyu, failed to meet the main target in a Phase 3 clinical study. The drug was unable to show it could preserve vision with fewer injections when compared to the curren